SEC Form 4 · accession 0000939767-17-000073
EXELIXIS, INC. · EXEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gisela Schwab
Officer — Pres Prod Dev & Med Aff & CMO
Period of report
May 1, 2017
Accepted (ET)
May 3, 2017 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000939767
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 1, 2017 | M | 89,910 | $9.91 | A | 260,414 | D | |
| Common StockF3 | May 1, 2017 | S | 88,010 | $23.00 | D | 172,404 | D | |
| Common StockF4 | May 1, 2017 | S | 1,900 | $23.31 | D | 170,504 | D | |
| Common StockF5 | holding | — | — | — | 14,186 | I | By 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F6 | $9.91 | May 1, 2017 | M | 89,910 | D | Dec 6, 2008 | Dec 5, 2017 | Common Stock | 89,910 | 100,000 | D |
Explanation of responses
- F1Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 2,361 shares of common stock acquired on April 28, 2017, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.
- F2The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2017.
- F3Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.23 to $23.21. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
- F4Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.24 to $23.37. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
- F5Represents 14,186 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 1, 2017.
- F6The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011.